TY - JOUR AU - Günthard, H. F. AU - Aberg, J. A. AU - Eron, J. J. AU - Hoy, J. F. AU - Telenti, A. AU - Benson, C. A. PY - 2014 DA - 2014// TI - Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel JO - JAMA VL - 312 UR - https://doi.org/10.1001/jama.2014.8722 DO - 10.1001/jama.2014.8722 ID - Günthard2014 ER - TY - JOUR PY - 2012 DA - 2012// TI - Summary report from the human immunodeficiency virus and aging consensus project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus JO - J Am Geriatr Soc VL - 60 UR - https://doi.org/10.1111/j.1532-5415.2012.03948.x DO - 10.1111/j.1532-5415.2012.03948.x ID - ref2 ER - TY - STD TI - DHHS, US Department of Health and Human Services (DHHS). Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. UR - https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf ID - ref3 ER - TY - STD TI - U.S. Department of Health and Human Services, Food and Drug Administration. Size, shape, and other physical attributes of generic tablets and capsules guidance for industry. June 2015. ID - ref4 ER - TY - JOUR AU - Greig, S. L. AU - Deeks, E. D. PY - 2015 DA - 2015// TI - Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection JO - Drugs VL - 75 UR - https://doi.org/10.1007/s40265-015-0361-6 DO - 10.1007/s40265-015-0361-6 ID - Greig2015 ER - TY - JOUR AU - Min, S. AU - Sloan, L. AU - Jesus, E. AU - Hawkins, T. AU - McCurdy, L. AU - Song, I. PY - 2011 DA - 2011// TI - Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults JO - AIDS VL - 25 UR - https://doi.org/10.1097/QAD.0b013e32834a1dd9 DO - 10.1097/QAD.0b013e32834a1dd9 ID - Min2011 ER - TY - JOUR AU - Cottrell, M. L. AU - Hadzic, T. AU - Kashuba, A. D. PY - 2013 DA - 2013// TI - Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir JO - Clin Pharmacokinet VL - 52 UR - https://doi.org/10.1007/s40262-013-0093-2 DO - 10.1007/s40262-013-0093-2 ID - Cottrell2013 ER - TY - JOUR AU - Gubavu, C. AU - Prazuck, T. AU - Niang, M. AU - Buret, J. AU - Mille, C. AU - Guinard, J. PY - 2016 DA - 2016// TI - Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients JO - J Antimicrob Chemother VL - 71 UR - https://doi.org/10.1093/jac/dkv430 DO - 10.1093/jac/dkv430 ID - Gubavu2016 ER - TY - JOUR AU - Rojas, J. AU - Blanco, J. L. AU - Marcos, M. A. AU - Lonca, M. AU - Tricas, A. AU - Moreno, L. PY - 2016 DA - 2016// TI - Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression JO - J Antimicrob Chemother VL - 71 UR - https://doi.org/10.1093/jac/dkw078 DO - 10.1093/jac/dkw078 ID - Rojas2016 ER - TY - JOUR AU - Deguchi, K. AU - Ikeda, K. AU - Kume, K. AU - Takata, T. AU - Kokudo, Y. AU - Kamada, M. PY - 2015 DA - 2015// TI - Significance of the hot-cross bun sign on T2*-weighted MRI for the diagnosis of multiple system atrophy JO - J Neurol VL - 262 UR - https://doi.org/10.1007/s00415-015-7728-1 DO - 10.1007/s00415-015-7728-1 ID - Deguchi2015 ER - TY - JOUR AU - Jamroz-Wiśniewska, A. AU - Jaworski, J. AU - Suszek, D. AU - Janczarek, M. AU - Stelmasiak, Z. AU - Rejdak, K. PY - 2014 DA - 2014// TI - Disappearance of white matter lesions on MRI and clinical recovery after initiating antiretroviral therapy in a case of HIV infection presenting as spastic paraparesis JO - Neurol Neurochir Pol VL - 48 ID - Jamroz-Wiśniewska2014 ER - TY - JOUR AU - Brew, B. J. PY - 2007 DA - 2007// TI - Neurological Sequelae of primary HIV infection JO - Handb Clin Neurol VL - 85 UR - https://doi.org/10.1016/S0072-9752(07)85005-6 DO - 10.1016/S0072-9752(07)85005-6 ID - Brew2007 ER - TY - JOUR AU - Mochan, A. AU - Modi, M. AU - Modi, G. PY - 2003 DA - 2003// TI - Stroke in black south African HIV-positive patients: a prospective analysis JO - Stroke VL - 34 UR - https://doi.org/10.1161/01.STR.0000043821.35051.FA DO - 10.1161/01.STR.0000043821.35051.FA ID - Mochan2003 ER - TY - JOUR AU - Hey, H. AU - Jørgensen, F. AU - Sørensen, K. AU - Hasselbalch, H. AU - Wamberg, T. PY - 1982 DA - 1982// TI - Oesophageal transit of six commonly used tablets and capsules JO - Br Med J (Clin Res Ed) VL - 285 UR - https://doi.org/10.1136/bmj.285.6356.1717 DO - 10.1136/bmj.285.6356.1717 ID - Hey1982 ER - TY - JOUR AU - Channer, K. S. AU - Virjee, J. P. PY - 1986 DA - 1986// TI - The effect of size and shape of tablets on their esophageal transit JO - J Clin Pharmacol VL - 26 UR - https://doi.org/10.1002/j.1552-4604.1986.tb02922.x DO - 10.1002/j.1552-4604.1986.tb02922.x ID - Channer1986 ER - TY - JOUR AU - Jackson, L. D. AU - Little, J. AU - Kung, E. AU - Williams, E. M. AU - Siemiatkowska, K. AU - Plowman, S. PY - 2008 DA - 2008// TI - Safe medication swallowing in Dysphagia: a collaborative improvement project JO - Healthc Q VL - 11 UR - https://doi.org/10.12927/hcq.2008.19660 DO - 10.12927/hcq.2008.19660 ID - Jackson2008 ER - TY - JOUR AU - Cruciani, M. AU - Zanichelli, V. AU - Serpelloni, G. AU - Bosco, O. AU - Malena, M. AU - Mazzi, R. PY - 2011 DA - 2011// TI - Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data JO - AIDS VL - 25 UR - https://doi.org/10.1097/QAD.0b013e328349c6ee DO - 10.1097/QAD.0b013e328349c6ee ID - Cruciani2011 ER - TY - JOUR AU - Mallal, S. AU - Phillips, E. AU - Carosi, G. AU - Molina, J. M. AU - Workman, C. AU - Tomazic, J. PY - 2008 DA - 2008// TI - HLA-B*5701 screening for hypersensitivity to abacavir JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMoa0706135 DO - 10.1056/NEJMoa0706135 ID - Mallal2008 ER - TY - JOUR AU - Saag, M. AU - Balu, R. AU - Phillips, E. AU - Brachman, P. AU - Martorell, C. AU - Burman, W. PY - 2008 DA - 2008// TI - High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients JO - Clin Infect Dis VL - 46 UR - https://doi.org/10.1086/529382 DO - 10.1086/529382 ID - Saag2008 ER - TY - JOUR AU - Nishijima, T. AU - Kawasaki, Y. AU - Tanaka, N. AU - Mizushima, D. AU - Aoki, T. AU - Watanabe, K. PY - 2014 DA - 2014// TI - Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up JO - AIDS VL - 28 UR - https://doi.org/10.1097/QAD.0000000000000347 DO - 10.1097/QAD.0000000000000347 ID - Nishijima2014 ER - TY - JOUR AU - Goicoechea, M. AU - Liu, S. AU - Best, B. AU - Sun, S. AU - Jain, S. AU - Kemper, C. PY - 2008 DA - 2008// TI - Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy JO - J Infect Dis VL - 197 UR - https://doi.org/10.1086/524061 DO - 10.1086/524061 ID - Goicoechea2008 ER - TY - JOUR AU - Gallant, J. E. AU - Moore, R. D. PY - 2009 DA - 2009// TI - Renal function with use of a tenofovir-containing initial antiretroviral regimen JO - AIDS VL - 23 UR - https://doi.org/10.1097/QAD.0b013e32832c96e9 DO - 10.1097/QAD.0b013e32832c96e9 ID - Gallant2009 ER - TY - JOUR AU - Reynes, J. AU - Trinh, R. AU - Pulido, F. AU - Soto-Malave, R. AU - Gathe, J. AU - Qaqish, R. PY - 2013 DA - 2013// TI - Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study JO - AIDS Res Hum Retrovir VL - 29 ID - Reynes2013 ER - TY - JOUR AU - Raffi, F. AU - Babiker, A. G. AU - Richert, L. AU - Molina, J. M. AU - George, E. C. AU - Antinori, A. PY - 2014 DA - 2014// TI - Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)61170-3 DO - 10.1016/S0140-6736(14)61170-3 ID - Raffi2014 ER - TY - JOUR AU - Taiwo, B. AU - Zheng, L. AU - Gallien, S. AU - Matining, R. M. AU - Kuritzkes, D. R. AU - Wilson, C. C. PY - 2011 DA - 2011// TI - Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262) JO - AIDS VL - 25 UR - https://doi.org/10.1097/QAD.0b013e32834bbaa9 DO - 10.1097/QAD.0b013e32834bbaa9 ID - Taiwo2011 ER - TY - JOUR AU - Cahn, P. AU - Andrade-Villanueva, J. AU - Arribas, J. R. AU - Gatell, J. M. AU - Lama, J. R. AU - Norton, M. PY - 2014 DA - 2014// TI - Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial JO - Lancet Infect Dis VL - 14 UR - https://doi.org/10.1016/S1473-3099(14)70736-4 DO - 10.1016/S1473-3099(14)70736-4 ID - Cahn2014 ER - TY - JOUR AU - Margolis, D. A. AU - Brinson, C. C. AU - Smith, G. H. AU - Vente, J. AU - Hagins, D. P. AU - Eron, J. J. PY - 2015 DA - 2015// TI - Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(15)00152-8 DO - 10.1016/S1473-3099(15)00152-8 ID - Margolis2015 ER - TY - STD TI - ClinicalTrials.gov, Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults. Identifier: NCT02429791/NCT02422797 (accessed 21 Apr 2016). ID - ref28 ER -